David Scott Miller


AuthID: R-00K-250

Confirmed Publications: 319



11
TITLE: Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller ; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
12
TITLE: Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller ; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
13
TITLE: Supplementary Table S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller ; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
14
TITLE: Supplementary Table S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller ; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
15
TITLE: Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller ; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
16
TITLE: Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma
AUTHORS: William Vintzileos; Hannah Beer; David Scott Miller ; Jayanthi Lea;
PUBLISHED: 2025, SOURCE: Gynecologic Oncology Reports, VOLUME: 58
INDEXED IN: Scopus CrossRef Unpaywall
IN MY: ORCID
17
TITLE: Surgical Staging Identifies Occult Metastases in Over 50% of Uterine-Confined Carcinosarcoma
AUTHORS: William Vintzileos; Hannah Beer; David Scott Miller ; Jayanthi Lea;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
18
TITLE: 187 Selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
AUTHORS: Jalid Sehouli; Ignace Vergote; Erika Hamilton; Alejandro Pérez Fidalgo; Toon Van Gorp; Giovanni Scambia; Jaroslav Klat; Tally Levy; Stephen Welch; Debra L Richardson; Eva Maria Guerra Alía; Stéphanie Henry; Pauline Wimberger; David Scott Miller ; Jerónimo Martínez; Bradley J Monk; Pratheek Kalyanapu; Monsoor Raza Mirza; Vicky Makker;
PUBLISHED: 2024, SOURCE: Oral Sessions
INDEXED IN: CrossRef: 2
IN MY: ORCID | CIÊNCIAVITAE
19
TITLE: Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC).
AUTHORS: Jung-Yun Lee; Baek-Yeol Ryoo; Jin Won Kim; Ann-Lii Cheng; Richard S Finn; Kosei Hasegawa; Vicky Makker; Masatoshi Kudo; David Scott Miller ; Philippe Merle; Susanna Varkey Ulahannan; Tetsuya Hosaka; Takatoshi Sahara; Cixin S He; Karen O'Hara; Lea Dutta; Toshiyuki Tamai; Masafumi Ikeda;
PUBLISHED: 2024, SOURCE: Journal of Clinical Oncology, VOLUME: 42, ISSUE: 16_suppl
INDEXED IN: CrossRef
IN MY: ORCID | CIÊNCIAVITAE
20
TITLE: Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study  Full Text
AUTHORS: Vicky Makker; Jose Alejandro Perez Fidalgo; Giorgio Valabrega; Erika Hamilton; Toon Van Gorp; Jalid Sehouli; Klaudia Regináčová; Debra L Richardson; Tamar Perri; Amit M Oza; David Scott Miller ; Eva Maria Guerra Alía; Ugo De Giorgi; Stephanie Henry; Daniel L Spitz; Pauline Wimberger; Markéta Bednaříková; Hye Sook Chon; Jerónimo Martínez Garcia; Carmela Pisano; Jonathan S Berek; Ignacio Romero; Giovanni Scambia; Lorena Fariñas Madrid; Joseph Buscema; Fabienne Schochter; Kai Li; Pratheek Kalyanapu; Christopher J Walker; Ignace Vergote; ...More
PUBLISHED: 2024, SOURCE: Gynecologic Oncology, VOLUME: 185
INDEXED IN: Scopus CrossRef: 3
IN MY: ORCID | CIÊNCIAVITAE
Page 2 of 32. Total results: 319.

footer slogan

Useful Links

Get Help

© 2025 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service